These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10587769)

  • 21. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.
    Shah NC; Pringle SD; Donnan PT; Struthers AD
    J Hypertens; 2007 Nov; 25(11):2345-51. PubMed ID: 17921831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF; Overdiek JW; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
    Dinsdale C; Wani M; Steward J; O'Mahony MS
    Age Ageing; 2005 Jul; 34(4):395-8. PubMed ID: 15955761
    [No Abstract]   [Full Text] [Related]  

  • 24. [Medical treatment of heart failure: old facts in new lights].
    Angehrn W
    Schweiz Med Wochenschr; 2000 Jan; 130(1-2):25-7. PubMed ID: 10670042
    [No Abstract]   [Full Text] [Related]  

  • 25. [Randomized Aldactone Evaluation Study (RALES)].
    Uchida K; Nakano S; Kigoshi T
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():330-5. PubMed ID: 15813090
    [No Abstract]   [Full Text] [Related]  

  • 26. Hyperkalemia after the publication of RALES.
    Goldfarb DS
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15575065
    [No Abstract]   [Full Text] [Related]  

  • 27. [New evidence for the usefulness of an old drug in the treatment of heart failure].
    Oseguera Moguel J
    Rev Invest Clin; 2000; 52(1):14-6. PubMed ID: 10818804
    [No Abstract]   [Full Text] [Related]  

  • 28. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
    Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
    J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
    Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT; Juurlink DN; Mamdani MM; You JJ; Wang JT; Donovan LR; Tu JV
    J Card Fail; 2006 Apr; 12(3):205-10. PubMed ID: 16624686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of spironolactone in heart failure should be emphasised.
    Mapstone J; Houston B; Gogarty M
    BMJ; 2000 Sep; 321(7262):706-7. PubMed ID: 11202944
    [No Abstract]   [Full Text] [Related]  

  • 32. Spironolactone use in patients with heart failure.
    Trujillo JM; Gonyeau MJ; DiVall MV; Alexander SL
    J Clin Pharm Ther; 2004 Apr; 29(2):165-70. PubMed ID: 15068406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [No effect of spironolactone on bulimia nervosa symptoms].
    von Wietersheim J; Müller-Bock V; Rauh S; Danner B; Chrenko K; Bühler G
    Psychother Psychosom Med Psychol; 2008 Dec; 58(12):470-4. PubMed ID: 18666040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Increased breast cancer risk caused by spironolactone?].
    Fanta S
    Dtsch Med Wochenschr; 2012 Sep; 137(38):1840. PubMed ID: 23133848
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of heart failure with spironolactone--trial and tribulations.
    McMurray JJ; O'Meara E
    N Engl J Med; 2004 Aug; 351(6):526-8. PubMed ID: 15295043
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure.
    Feola M; Menardi E; Ribichini F; Vado A; Deorsola A; Ferrero V; Visconti G; Milanese U; Uslenghi E
    Med Sci Monit; 2003 Aug; 9(8):CR341-5. PubMed ID: 12942029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spironolactone and congestive heart-failure.
    Georges B; Beguin C; Jadoul M
    Lancet; 2000 Apr; 355(9212):1369-70. PubMed ID: 10776778
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of spironolactone therapy in patients with heart failure with normal ejection fraction.
    Ozhan H; Balaban Y
    Heart; 2010 May; 96(10):791; author reply 791. PubMed ID: 20448132
    [No Abstract]   [Full Text] [Related]  

  • 39. [Antikaliuretic agents].
    Esch I
    Internist (Berl); 1971 Aug; 12():Suppl:352-6. PubMed ID: 4937775
    [No Abstract]   [Full Text] [Related]  

  • 40. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
    Berry C; McMurray JJ
    Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.